Prostate-specific antigen bounce in patients treated before 60 years old by iodine 125 brachytherapy for prostate cancer is frequent and not a prognostic factor.
Fiche publication
Date publication
août 2018
Journal
Brachytherapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERNIER-CHASTAGNER Valérie, Dr ESCHWEGE Pascal, Pr PEIFFERT Didier
Tous les auteurs :
Charret J, Baumann AS, Eschwege P, Moreau JL, Bernier V, Falk AT, Salleron J, Peiffert D
Lien Pubmed
Résumé
The only prognostic factor of prostate-specific antigen (PSA) bounce in prostate cancer found in several studies is young age but has never been specifically studied in this subset of patients for long-term results. Bounce characteristics, histological, clinical, and dosimetric data in young patients were analyzed, as well as their impact on toxicity and survival.
Mots clés
Brachytherapy, PSA bounce, Prostate cancer, Young people
Référence
Brachytherapy. 2018 Aug 29;: